Featured Publications
Women with PCOS who undergo IVF: a comprehensive review of therapeutic strategies for successful outcomes
Kotlyar A, Seifer D. Women with PCOS who undergo IVF: a comprehensive review of therapeutic strategies for successful outcomes. Reproductive Biology And Endocrinology 2023, 21: 70. PMID: 37528417, PMCID: PMC10391774, DOI: 10.1186/s12958-023-01120-7.Peer-Reviewed Original ResearchMeSH KeywordsFemaleFertilization in VitroGonadotropin-Releasing HormoneHumansInfertility, FemaleOvarian Hyperstimulation SyndromeOvulation InductionPolycystic Ovary SyndromePregnancyPregnancy RateConceptsPolycystic ovarian syndromeOvarian hyperstimulation syndromeOvarian stimulationStimulation protocolFrozen embryo transfer cyclesVitamin D repletionGnRH agonist triggerVitamin D levelsEmbryo transfer cyclesOvarian stimulation protocolsAntagonist cyclesHyperstimulation syndromeHypertensive disordersIVF cyclesPCOS patientsAgonist triggerOvarian syndromeOocyte yieldD levelsImproved outcomesPregnancy rateCommon causeIVF performanceTherapeutic courseInfertile couples
2015
The Emerging Role of Angiogenic Factor Dysregulation in the Pathogenesis of Polycystic Ovarian Syndrome
Tal R, Seifer DB, Arici A. The Emerging Role of Angiogenic Factor Dysregulation in the Pathogenesis of Polycystic Ovarian Syndrome. Seminars In Reproductive Medicine 2015, 33: 195-207. PMID: 26036901, DOI: 10.1055/s-0035-1552582.Peer-Reviewed Original ResearchConceptsPolycystic ovarian syndromeGrowth factorOvarian syndromePathophysiology of PCOSAngiogenic factor imbalanceOvarian hyperstimulation syndromeCommon endocrine disorderVascular endothelial growth factorPlatelet-derived growth factorBasic fibroblast growth factorMultiple angiogenic factorsEndothelial growth factorFibroblast growth factorHyperstimulation syndromeOvulatory dysfunctionStromal vascularityAnovulatory infertilityPolycystic ovariesEndocrine disordersReproductive ageTreatment strategiesFollicular growthOvarian angiogenesisAngiogenic factorsCorpus luteum
2013
Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation
Tal R, Seifer DB, Shohat-Tal A, Grazi RV, Malter HE. Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation. Fertility And Sterility 2013, 100: 538-543. PMID: 23684116, DOI: 10.1016/j.fertnstert.2013.04.022.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigens, CDCase-Control StudiesEndoglinFemaleFertilization in VitroFollicular FluidHumansInfertility, FemaleOvarian Hyperstimulation SyndromeOvulation InductionPolycystic Ovary SyndromeReceptors, Cell SurfaceSperm Injections, IntracytoplasmicTransforming Growth Factor beta1UltrasonographyYoung AdultConceptsPolycystic ovarian syndromeSerum soluble endoglinDay of hCGSoluble endoglinFollicular fluidTGF-β1Oocyte retrievalOvarian stimulationHCG administrationControl womenDay 3Pathogenesis of PCOSNon-PCOS control groupProspective case-control studyNon-PCOS controlsSerum TGF-β1Non-PCOS womenPolycystic ovary syndromeTGF-β1 levelsReproductive technology unitCase-control studyGrowth factor-β1Day of retrievalOvarian hyperstimulationOvarian syndrome
2007
Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance
Seifer DB, MacLaughlin DT. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertility And Sterility 2007, 88: 539-546. PMID: 17559842, DOI: 10.1016/j.fertnstert.2007.02.014.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Mullerian HormoneFemaleGlycoproteinsGranulosa Cell TumorHumansMenstrual CycleOvarian Hyperstimulation SyndromeOvarian NeoplasmsOvaryOvulation InductionPolycystic Ovary SyndromeTesticular HormonesConceptsPolycystic ovarian diseaseMullerian Inhibiting SubstanceOvarian reserveOvulation inductionInhibiting SubstanceDiagnosis of PCODRisk of OHSSOvarian growth factorsWidespread clinical useOvarian hyperstimulationOvarian diseaseOvarian functionMEDLINE reviewClinical significanceIntracycle variabilityEarly markerClinical useConventional markersDiagnostic markerGrowth factorSpecific cutIntercycle variabilityDifferent assaysMarkersDiagnosis
2001
Single blastocyst transfer in women at risk of ovarian hyperstimulation syndrome
Trout S, Bohrer M, Seifer D. Single blastocyst transfer in women at risk of ovarian hyperstimulation syndrome. Fertility And Sterility 2001, 76: 1066-1067. PMID: 11704139, DOI: 10.1016/s0015-0282(01)02838-2.Peer-Reviewed Original Research
1994
Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors*
Lyons CA, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning RV. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors*. Human Reproduction 1994, 9: 792-799. PMID: 7929724, DOI: 10.1093/oxfordjournals.humrep.a138598.Peer-Reviewed Original ResearchMeSH KeywordsChorionic GonadotropinEmbryo TransferEstradiolFemaleFertilization in VitroHumansOocytesOvarian Hyperstimulation SyndromeOvulation InductionPregnancyPregnancy ComplicationsProgesteroneRisk FactorsTime FactorsConceptsLate ovarian hyperstimulation syndromeOvarian hyperstimulation syndromeSevere ovarian hyperstimulation syndromeNumber of oocytesHyperstimulation syndromeEarly ovarian hyperstimulation syndromePost-human chorionic gonadotrophinDifferent risk factorsStepwise logistic regressionSeries of casesDay-hCGMultiple gestationsClinical predictorsFertilization cyclesGestational sacEarly pregnancyLate presentationOestradiol concentrationsSerum concentrationsEgg retrievalRisk factorsHigh oestradiolAcute effectsChorionic gonadotrophinRetrospective analysis